XML 69 R57.htm IDEA: XBRL DOCUMENT
v3.21.2

Asset Acquisitions and Collaboration Agreement - Additional Information (Details) - USD ($) |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2018 | Sep. 30, 2021 | Sep. 30, 2021 | Dec. 31, 2018 | May 31, 2021 | Jan. 01, 2021 | [1] | Dec. 31, 2020 | [2]
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
Amortization expenses |  | $ 700,000 | $ 1,300,000 |  |  |  |  |
Amortization expenses, remainder period |  | 1,200,000 | 1,200,000 |  |  |  |  |
Amortization expenses, 2022 |  | 3,700,000 | 3,700,000 |  |  |  |  |
Amortization expenses, 2023 |  | 3,700,000 | 3,700,000 |  |  |  |  |
Amortization expenses, 2024 |  | 3,700,000 | 3,700,000 |  |  |  |  |
Amortization expenses, 2025 |  | 3,700,000 | 3,700,000 |  |  |  |  |
Amortization expenses, thereafter |  | 30,000,000.0 | 30,000,000.0 |  |  |  |  |
Capitalization of finite-lived intangible asset |  | 46,204,000 | 46,204,000 |  |  |  |  |
Other long-term liabilities |  | 27,578,000 | 27,578,000 |  |  | $ 8,425,000 | $ 9,520,000 | [1]
Other accrued liabilities |  | 14,608,000 | 14,608,000 |  |  |  | $ 13,349,000 |
Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc |  |  |  |  |  |  |  |
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
Capitalization of finite-lived intangible asset |  |  |  |  | $ 12,500,000 |  |  |
Payment Following FDA Approval of Truseltiq |  |  |  |  |  |  |  |
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
Regulatory milestone payments |  |  |  |  | $ 20,000,000.0 |  |  |
QED Therapeutics, Inc | Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc |  |  |  |  |  |  |  |
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
Regulatory milestone payments | $ 12,500,000 |  |  |  |  |  |  |
Regulatory milestone payments term | 4 years |  |  |  |  |  |  |
Other long-term liabilities |  | 11,000,000.0 | 11,000,000.0 |  |  |  |  |
Other accrued liabilities |  | 1,500,000 | 1,500,000 |  |  |  |  |
QED Therapeutics, Inc | Maximum |  |  |  |  |  |  |  |
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
Regulatory milestone payments |  |  |  | $ 60,000,000.0 |  |  |  |
Sales-based milestone payments |  |  |  | 35,000,000.0 |  |  |  |
Origin Biosciences, Inc. |  |  |  |  |  |  |  |
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
One-time final payment |  | $ 15,000,000.0 | $ 15,000,000.0 |  |  |  |  |
Origin Biosciences, Inc. | Maximum |  |  |  |  |  |  |  |
Business Acquisition Equity Interests Issued Or Issuable [Line Items] |  |  |  |  |  |  |  |
Sales-based milestone payments |  |  |  | 17,000,000.0 |  |  |  |
Assets acquisition required milestone payments |  |  |  | $ 18,800,000 |  |  |  |
[1] | Related deferred tax liability was recorded as part of “Other long-term liabilities.”
[2] | The condensed consolidated balance sheet as of December 31, 2020 is derived from the audited consolidated financial statements as of that date.

X
- Definition Assets acquisition required milestone payments. + References No definition available. + Details
Name: | bbio_AssetsAcquisitionRequiredMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Finite lived intangible assets amortization expense rolling after year four. + References No definition available. + Details
Name: | bbio_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition One time final payment. + References No definition available. + Details
Name: | bbio_OneTimeFinalPayment
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential regulatory milestone payments. + References No definition available. + Details
Name: | bbio_RegulatoryMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory milestone payments term. + References No definition available. + Details
Name: | bbio_RegulatoryMilestonePaymentsTerm
Namespace Prefix: | bbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestone payments. + References No definition available. + Details
Name: | bbio_SalesMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765 + Details
Name: | us-gaap_OtherAccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_FoundationMedicineDiagnosticsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_FoundationMedicineIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bbio_PaymentFollowingFDAApprovalOfTruseltiqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bbio_QEDTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bbio_OriginBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |